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ABSTRACT
Purpose: The oral fluoropyrimidine S-1, which consists
of a mixture of a 5-fluorouracil (5-FU) prodrug (tegafur), a
dihydropyrimidine dehydrogenase inhibitor [5-chloro-2,4-
dihydroxypyrimidine (CDHP)], and an inhibitor of orotate
phosphoribosyltransferase [potassium oxonate (oxonic
acid)], was developed to increase the feasibility and thera-
peutic index of 5-FU administered orally. The principal
objective of this study was to assess the feasibility of admin-
istering S-1 on a once-daily-for-28-day schedule every 5
weeks, determine the maximum tolerated dose, characterize
the pharmacokinetics of S-1, and seek evidence of anticancer
activity.
Experimental Design: Patients with advanced solid ma-
lignancies were treated with escalating doses of S-1 on a
once-daily oral schedule for 28 days every 5 weeks. The
maximum tolerated dose was defined as the highest dose in
which fewer than two of the first six new patients experi-
enced dose-limiting toxicity. The pharmacokinetic profiles
of the tegafur, CDHP, and oxonic acid constituents were
characterized.
Results: Twenty patients were treated with 72 courses
of S-1 at three dose levels ranging from 50 to 70 mg/m2/day.
Diarrhea, which was often associated with abdominal dis-
comfort and cramping, was the principal dose-limiting tox-
icity of S-1 on this protracted schedule. Nausea, vomiting,
mucositis, fatigue, and cutaneous effects were also observed
but were rarely severe. Myelosuppression was modest and
uncommon. A partial response and a 49% reduction in
tumor size were observed in patients with fluoropyrimidine-
and irinotecan-resistant colorectal carcinoma. The pharma-
cokinetic data suggested potent inhibition of 5-FU clearance
by CHDP, with resultant 5-FU exposure at least 10-fold
higher than that reported from equitoxic doses of tegafur
modulated by uracil in the oral fluoropyrimidine UFT.
Conclusions: The recommended dose for Phase II stud-
ies of S-1 administered once daily for 28 consecutive days
every 5 weeks is 50 mg/m2/day. The pharmacokinetic data
indicate substantial modulation of 5-FU clearance by
CDHP. Based on these pharmacokinetic data, the predict-
able toxicity profile of S-1, and the low incidence of severe
adverse effects at the recommended Phase II dose, evalua-
tions of S-1 on this schedule are warranted in malignancies
that are sensitive to the fluoropyrimidines.
INTRODUCTION
The fluoropyrimidines have been the mainstay of therapy
for the management of colorectal and other gastrointestinal
malignancies since the introduction of 5-fluorouracil (5-FU)
into practice in the 1950s (1). Over the last several decades,
many methods of fluorpyrimidine administration and biochem-
ical modulation strategies have been investigated to improve the
overall efficacy and therapeutic index of this class of antime-
tabolites (1–11). In patients with advanced colorectal cancer,
regimens that result in continuous fluoropyrimidine exposure,
particularly protracted intravenous infusions, have consistently
demonstrated higher response rates and more favorable toxicity
profiles than intermittent bolus and short infusion schedules
(1–9). Despite these results, protracted intravenous infusional
methods have not been widely adopted because of the costs,
cumbersomeness, and inconvenience associated with the re-
quirements for central venous catheters and portable infusion
pumps, as well as a the absence of a clear survival advantage.
Furthermore, 5-FU itself is associated with large interpatient
variability in pharmacokinetics and, in turn, pharmacodynamics,
largely due to substantial interindividual variability in the prin-
cipal catabolic enzyme of 5-FU, dihydropyrimidine dehydro-
genase, which impedes the utility of 5-FU administered both
parenterally and orally (12–17).
Although daily oral 5-FU administration represents an attrac-
tive alternate means of achieving protracted 5-FU exposure, the
high dihydropyrimidine dehydrogenase activity in the liver results
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in low, variable, and unpredictable systemic bioavailability (12–
16). The development of 5-FU prodrugs represents efforts directed
at increasing oral bioavailability as well as developing oral sched-
ules that simulate protracted intravenous 5-FU administration. The
oral 5-FU prodrug tegafur (5-fluoro-1-[tetrahydro-2-furanyl]-
2,4[1H,3H]pyrimidinedione) is metabolically activated to 5-FU by
hepatic microsomes (18). UFT, a combination of tegafur and the
dihydropyrimidine dehydrogenase inhibitor uracil, achieves rele-
vant systemic 5-FU concentrations, achieves relevant antitumor
activity in fluoropyrimidine-sensitive neoplasms, and has under-
gone regulatory approval in many countries worldwide for treat-
ment of patients with colorectal cancer (18). S-1, which contains
tegafur, 5-chloro-2,4-dihydropyridine (CDHP), and potassium ox-
onate (oxonic acid) in a fixed molar ratio of 1:0.4:1 based on
cytotoxicity studies in Yoshida sarcoma-bearing rats and human
gastric cancer xenografts, was developed to further enhance the
therapeutic index of tegafur administered orally (19). When tegafur
is combined with CDHP, which is 180-fold more potent than uracil
at inhibiting dihydropyrimidine dehydrogenase in vitro, biologi-
cally relevant plasma 5-FU concentrations are sustained in both
plasma and tumors (19–21). The rationale for oxonic acid as a
constituent of S-1 is its potential to reduce gastrointestinal toxicity
by inhibiting orotate phosphoribosyl transferase and, in turn, 5-FU
phosphorylation or activation in gastrointestinal tissues (21–22).
Therefore, oxonic acid may reduce gastrointestinal toxicity without
impeding the antitumor activity of 5-FU due to the inhibitory
effects of 5-FU on thymidylate synthase and DNA synthesis as well
the antimetabolic effects of 5-FU on RNA.
The antitumor activity of S-1 was established in various
experimental models including rodent tumors and human xe-
nografts (19, 21–23). In studies in which the antitumor effects of
S-1 and UFT were compared, S-1 demonstrated superior activity
against human gastric, colorectal, and breast cancer xenografts
(24). Furthermore, S-1 demonstrated greater antitumor activity
and less toxicity than 5-FU administered as a protracted infusion
(25). The initial clinical development of S-1 involved twice
daily dosing for 21–28 days followed by a 7-day rest period
(26–28). Diarrhea was the principal dose-limiting toxicity, and
recommended doses ranged from 30 to 35 mg/m2. In Phase II
studies, S-1 demonstrated notable activity in patients with ad-
vanced gastric, colorectal, breast, and head and neck cancers,
and the agent has received regulatory approval in Japan for
patients with advanced gastric cancer (29–36).
This Phase I and pharmacokinetic study of S-1 was under-
taken to evaluate the feasibility, safety, and pharmacokinetics of
a once-daily schedule to improve the safety, tolerability, con-
venience, and possibly compliance of S-1 while maintaining
efficacy. It was reasoned that prolonged inhibition of dihydro-
pyrimidine dehydrogenase by CDHP with resultant diminution
of 5-FU clearance might render once-daily dosing feasible. The
principal objectives of this study were as follows (a) to deter-
mine the maximum tolerated dose of S-1 administered once
daily for 28 days, repeated every 5 weeks and to recommend a
dose for Phase II trials; (b) to characterize the toxicities asso-
ciated with this schedule of administration; (c) to describe the
pharmacokinetic behavior of S-1 on this schedule; and (d) to
seek preliminary evidence for antitumor activity.
PATIENTS AND MATERIALS
Patient Selection. Patients with histologically or cyto-
logically confirmed advanced solid malignancies who failed to
respond to standard therapy or for whom adequate therapy was
not available were eligible. Eligibility criteria also included the
following: age  18 years; an Eastern Cooperative Oncology
Group performance status  2; life-expectancy of 3 months;
no chemotherapy, immunotherapy, or radiation therapy within 4
weeks of treatment (6 weeks for nitrosoureas and mitomycin C
and 8 weeks for irreversible dihydropyrimidine dehydrogenase
inhibitors); adequate hematopoietic (absolute neutrophil
count  1500/l, hemoglobin level  9.0 g/dl, platelet count 
100,000/l), hepatic (transaminases  2.0 institutional nor-
mal upper limit, total bilirubin  1.5 institutional normal
upper limit), and renal (creatinine  1.5 upper institutional
normal limit) functions; no chronic enteropathy or history of
gastric or small intestinal resections; measurable or evaluable
disease; and no coexisting medical conditions of sufficient se-
verity to limit compliance with the study. All concurrent med-
ications were recorded in the case report form. Patients gave
written informed consent before treatment, according to federal
and institutional guidelines.
Dosage and Drug Administration. S-1 was adminis-
tered once daily for 28 days every 5 weeks, which was defined
as a single course. The starting dose of S-1 was 50 mg/m2 once
daily, which was equivalent to approximately two thirds of the
maximally tolerated daily dose of S-1 on a twice-daily dosing
schedule (35 mg/m2 twice daily; Ref. 26). The maximum tol-
erated dose was defined as the highest dose at which fewer than
two of the first six patients experienced dose-limiting toxicity
during the first or second courses of treatment. The dose of S-1
was to be escalated in successive cohorts of new patients to 60,
70, and 80 mg/m2/day or reduced to 40 mg/m2/day if the starting
dose exceeded the maximum tolerated dose. At least three
patients were to be treated at each dose level that did not result
in dose-limiting toxicity during the first two courses. If one of
the initial three patients developed dose-limiting toxicity in
courses 1 or 2, then three additional patients were to be entered
on the same dose level. At least 10 additional patients could be
treated at the maximum tolerated dose. Dose-limiting toxicity
was defined as follows: (a) grade 3 nonhematological toxicity
(excluding nausea, vomiting, or diarrhea associated with subop-
timal premedication and/or management); (b) any grade 4 non-
hematological toxicity; (c) platelets  25,000/l or 50,000/l
associated with hemorrhage; (d) absolute neutrophil count of
500/l lasting more than 3 days; (e) absolute neutrophil count
of 1,000/l associated with fever (38.5°C); (f) omission of
25% of the planned dose of S-1 due to toxicity; (g) any
unresolved toxicity requiring a delay in the administration of a
subsequent course exceeding 14 days; and (h) any grade 2
toxicity which, in the judgment of the investigator and sponsor,
required dose reduction or discontinuation of therapy. Toxicity
was graded according to the National Cancer Institute Common
Toxicity Criteria Version 2.0.
Treatment was immediately discontinued in the event of
the following toxicities: platelets  50,000/l; absolute neutro-
phil count  1,000/l; or grade 2 nonhematological toxicity.
Following resolution of the toxicity to grade 1 within the
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28-day course, S-1 was resumed at the same dose level as long
as the event was not dose-limiting. In the event of dose-limiting
toxicity, treatment was not resumed until the planned date of the
next course, at which time the dose of S-1 was reduced by one
level. Dose escalation was permitted in individual patients who
had completed at least two courses of S-1 with grade 1
toxicity as long as at least one patient had completed two
courses of S-1 at the next higher dose level without grade 2
toxicity.
S-1 was supplied by Bristol-Myers Squibb Pharmaceutical
Research Institute (Wallingford, CT). Each capsule contained
20 or 25 mg of tegafur, with the tegafur, CDHP, and oxonic acid
constituents in a molar ratio of 1:0.4:1. Doses were calculated
according to body surface area. For patients with body surface
areas exceeding 2.0 m2, the S-1 dose was calculated based on a
body surface area equivalent to 2.0 m2. The calculated dose of
S-1 was rounded to the nearest 5 mg. Patients were instructed to
administer S-1 within 1 h after breakfast between 7 and 10 a.m.
because of the potential instability of oxonic acid in acid con-
ditions.
Pretreatment and Follow-Up Studies. Histories that in-
cluded recording of performance status, interval toxicities, and
concurrent medications, physical examinations, complete blood
counts, electrolytes, and chemistries were performed pretreat-
ment and weekly. Pretreatment studies also included an electro-
cardiogram and a pregnancy test in women of childbearing
potential and relevant radiological studies for evaluation of all
measurable or evaluable sites of malignancy, as well as an
assessment of relevant tumor markers. Radiological studies for
disease status assessments were repeated after every other
course or as needed to confirm response. Patients were able to
continue treatment if they did not develop progressive disease.
A complete response was scored if there was disappearance of
all active disease on two measurements separated by a minimum
period of 4 weeks, and a partial response required at least a 50%
reduction in the sum of the product of the bidimensional meas-
urements of all lesions documented separated by at least 4
weeks. Any concurrent increase in the size of any lesion by
25% or the appearance of any new lesion was considered
disease progression.
Pharmacokinetic and Pharmacodynamic Analyses.
Blood samples in heparinized tubes were collected on days 7,
14, and 21 of the first course before treatment to measure plasma
concentrations of 5-FU, CDHP, and oxonic acid. On day 28,
samples were also collected pretreatment and at 15, 30, 60, and
90 min and 2, 3, 5, 8, and 24 h after treatment. The samples were
centrifuged for 15 min at 1000  g at 0°C to 5°C immediately
after collection. Next, a 1-ml aliquot of plasma was transferred
to a sample tube, which was frozen at 70°C until assayed.
Tegafur was assayed using high-performance liquid chromatog-
raphy with UV detection with a standard curve range of 10–
4000 ng/ml (37). 5-FU, CDHP, and oxonic acid were assayed
using gas chromatography with mass spectrometric detection
using standard curve ranges of 1–400, 2–800, and 1–200 ng/ml,
respectively (37).
The plasma concentration-time data were analyzed using
noncompartmental methods (24 of mer). The peak plasma con-
centrations (Cmax) and time to peak plasma concentration (Tmax)
were obtained by experimental observations. Using no weight-
ing factor, the terminal log-linear phase of the concentration-
time curve was identified by least squares linear regression of at
least three data points, which yielded a minimum mean square
error. The elimination half-life (t1/2) was calculated as 0.693/K,
where K is the absolute value of the slope of the terminal
log-linear phase. The AUC from zero to infinity (AUC0-) was
equivalent to the sum of the areas from time zero to the time of
the last measured concentration, calculated by using the linear
trapezoidal method (until Cmax) and the log-trapezpoidal
method (until the last measurable concentration), and the ex-
trapolated area. The extrapolated area was determined by divid-
ing the final measured concentration by the slope of the terminal
log-linear phase. AUC over the dosing interval, AUC(TAU),
AUC from 0 to the last measurable plasma concentration, was
determined using linear trapezoidal and log-trapezoidal meth-
ods. Trough values on days 7, 14, and 21 were averaged on each
day for each dose level. The relationships between pharmaco-
kinetic parameters and toxicity were explored using Spearman
rank correlation analysis.
RESULTS
General. Twenty patients, whose pertinent characteris-
tics are listed in Table 1, were treated with 72 courses of S-1
through three planned dose levels ranging from 50 to 70 mg/
m2/day, and a fourth dose level, 40 mg/m2/day, was used for two
patients who required dose reduction due to toxicity at the 50
mg/m2/day dose level. Eighteen (90%) patients had either lo-
cally advanced or metastatic colorectal carcinoma that had been
previously treated with a fluoropyrimidine-based chemotherapy
Table 1 Patient characteristics
Characteristic No. of patients
No. of patients (fully evaluable) 20 (20)
Median no. of courses/patient (range) 3 (1–10)
Median age (range) (yrs) 60 (37–74)
Gender (M:F) 15:5
Median performance status (ECOG) 1
0 5
1 10
2 5
Previous therapy
Chemotherapy only 17
Chemotherapy and radiation 3
Previous chemotherapy
5-FU 18
Irinotecan 17
Carboplatin or cisplatin (6 courses) 2
Mitomycin C (2 courses) 1
Extent of prior myelosuppressive therapy*
Minimally pretreated* 14
Heavily pretreated* 6
Tumor types
Colorectal 18
Gastric 1
Lung (small cell) 1
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
* Heavily pretreated patients were defined retrospectively as those
subjects who received 6 courses of chemotherapy containing an alky-
lating agent (except low-dose cisplatin), 2 courses of a nitrosourea or
mitomycin C, radiation therapy to 25% of bone marrow-bearing
bones, or diffuse bone metastases.
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regimen. Six of the 20 (30%) patients were considered heavily
pretreated with respect to the extent of prior myelotoxic therapy
consisting of treatment with either wide-field radiation or car-
boplatin or mitomycin C. The total numbers of new patients
treated at each dose level, number of courses, and dose escala-
tion scheme are depicted in Table 2. All patients were fully
evaluable for toxicity. The median number of courses adminis-
tered per patient was 3 (range, 1–10). Three patients required
dose reduction on one occasion for either severe (grade 3) or
chronic grade 2 diarrhea, and one subject required dose reduc-
tion on two occasions. S-1 was administered at an unplanned
dose level, 40 mg/m2/day, in two individuals including one
patient who experienced grade 3 diarrhea after five courses of
S-1 at the 50 mg/m2/day dose level and a second patient who
required two sequential dose reductions for grade 2 diarrhea at
the 60 and 50 mg/m2/day dose levels.
After no or negligible drug-related adverse effects were
noted in the first two courses of the three patients treated at the
50 mg/m2/day dose level, the dose of S-1 was increased to 60
mg/m2/day. At 60 mg/m2/day, one of the first three patients
experienced dose-limiting toxicity, which consisted of grade 4
diarrhea and grade 3 mucositis in the first course; therefore,
three additional patients were treated and did not experience
unacceptable toxicity in courses 1 and 2. In contrast, dose-
limiting toxicity occurred in the first courses of all three indi-
viduals treated with S-1 at the 70 mg/m2/day dose level, which
resulted in further patient accrual at the next lower dose level.
Because the next two subjects treated with 60 mg/m2/day of S-1
also experienced dose-limiting toxicity in course 1, additional
patients were treated at the 50 mg/m2/day dose level. None of
nine new patients treated with 50 mg/m2/day of S-1 experienced
dose-limiting toxicity in both courses 1 and 2, and only one
dose-limiting toxicity was noted with repetitive treatment.
Based on these results, the maximum tolerated dose was deter-
mined to be 50 mg/m2/day.
Nonhematological Toxicity. The distributions of the
worst grade of the most common nonhematological toxicities of
S-1 experienced by each individual subject as a function of dose
level are displayed in Table 3. Diarrhea was the most common
adverse effect and principal dose-limiting toxicity of S-1. Fif-
teen (75%) patients experienced diarrhea at some time during
treatment. Both the incidence and severity of diarrhea appeared
to be dose-related within the narrow dose range evaluated. The
onset of diarrhea was typically during the third and fourth weeks
of treatment. In most patients, symptoms were mild to moderate
in severity and successfully managed with loperamide alone;
however, diarrhea also appeared to improve and/or resolve in
the 1-week planned rest period following the 28 days of daily
treatment. Severe (grade 3–4) diarrhea was experienced by five
patients, including three and two patients each at the 60 and 70
mg/m2/day dose levels, respectively. At 50 mg/m2/day, diarrhea
rarely precluded retreatment with each successive 4-week
course of S-1 following each planned 1-week rest period. The
exceptions were two patients who required dose reductions from
50 to 40 mg/m2/day. In the first individual, the dose was reduced
after seven courses due to recurrent grade 2 diarrhea, whereas
the dose was reduced twice in the second patient, initially from
60 to 50 mg/m2/day due to protracted grade 2 diarrhea, and then
again from 50 to 40 mg/m2/day due to severe (grade 3) diarrhea
in course 5. Other adverse effects, possibly related to the same
pathophysiological processes as diarrhea, included abdominal
pain, cramping, flatulence, and ileus. Overall, abdominal pain
and/or cramping were experienced by 45% of patients. Severe
(grade 4) abdominal discomfort concomitant with grade 2 or 3
diarrhea and ileus occurred in two patients who were treated
with 70 mg/m2/day of S-1. One of the subjects developed grade
2 diarrhea on days 11–13 of course 1 followed by ileus on day
21. Computerized tomographic scanning demonstrated that the
ileus was due to progressive intra-abdominal disease. The pa-
tient expired on day 24. The second patient developed a short-
lived ileus on the ninth day of his first course, which was felt to
be possibly related to S-1.
Hypokalemia, hyperkalemia, hypocalcemia, hypomag-
nesemia, and dehydration were infrequently noted in several
Table 2 Dose escalation scheme
S-1 dose
(mg/m2/day)
No. of patients
No. of
courses
No. of patients
with DLT
New
With dose
reduction Total
First two
courses
All
courses
40 0 2 2 4 0/0 0/4
50 9 3 12 47 0/9 1/47
60 8 1 9 18 4/8 4/18
70 3 0 3 3 3/3 3/3
Abbreviation: DLT, dose-limiting toxicity.
Table 3 Nonhematological toxicity
S-1 dose level
(mg/m2/day)
No. of patients
(courses)
Worst NCI CTC toxicity grade experienced per patient
Fatigue Anorexia Diarrhea Nausea
Abdominal
pain/cramping Vomiting Mucositis
1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4
40 2 (4) 0/1 0/0 0/0 0/0 1/1 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0 0/0
50 12 (47) 3/3 0/0 1/1 0/0 5/2 1/0 4/0 0/0 2/3 0/0 2/1 0/0 1/0 0/0
60 9 (18) 3/2 0/0 3/3 1/0 2/2* 1/1 4/1 1/0 1/0 0/0 2/1 0/0 0/2 1/0
70 3 (3) 0/0 0/0 0/1 1/0 0/1* 2/0 0/1 0/0 0/1 0/2 0/0 1/0 0/2 0/0
Abbreviations: NCI, National Cancer Institute; CTC, Common Toxicity Criteria.
* Although grade 2 in severity, two events and one event at 60 and 70 mg/m2/day were considered dose-limiting because S-1 treatment required
premature discontinuation.
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subjects who developed diarrhea. Fifty-five percent of patients
experienced anorexia; however, it was mild or moderate in most
cases. Furthermore, anorexia was noted across the entire S-1
dosing range, and definitive temporal relationships could not be
discerned, suggesting that the underlying malignant process may
have contributed. Two patients developed grade 3 anorexia;
however, one event occurred concomitant with rapid disease
progression, and the other event occurred in association with
diarrhea of grade 3 severity.
Nausea and vomiting, which were either mild (grade 1) or
moderate (grade 2) in severity, occurred in 50% and 35% of
patients, respectively. One patient treated with 70 mg/m2/day of
S-1 experienced severe (grade 3) nausea and vomiting. Nausea
and vomiting were prevented and/or managed successfully with
prochlorperazine, and routine premedication was not necessary
because most events consisted of nausea alone and were mild in
severity and sporadic. Thirty percent of patients complained of
mucositis at some time during treatment. Except for one subject
who experienced grade 3 mucositis associated with grade 4
diarrhea and several other gastrointestinal toxicities during the
first course of S-1 at the 60 mg/m2 dose level, all other events
were either mild or moderate in severity. The onset of mucositis
was typically following the second week of treatment and usu-
ally lasted 5–7 days. All events were uncomplicated. Mild
elevations in hepatic transaminases and/or serum bilirubin were
observed in 50% of patients; however, most episodes were
isolated, mild, asymptomatic, and occurred concurrent with
progression of liver metastases.
Dermatological manifestations, consisting principally of a
maculopapular rash and dry skin, were experienced by 45% of
patients. One patient each developed a typical, albeit mild
(grade 1), hand-foot syndrome and onycholysis after three and
five courses of S-1 at the 50 mg/m2/day dose level, respectively.
Four patients who received treatment with S-1 at doses of at
least 60 mg/m2 developed excessive lacrimation, which was
associated with a blocked lacrimal duct, conjunctival injection,
and blurred vision in one patient each.
Signs and symptoms resembling fluoropyrimidine-induced
cerebellar toxicity, including dizziness and vertigo, were expe-
rienced by three patients. Two subjects complained of mild,
noncumulative dizziness throughout nine and six courses at the
50 and 60 mg/m2/day dose levels, whereas another individual
developed grade 2 cerebellar symptoms concurrent with nausea,
vomiting, ileus, and dehydration in his first course of S-1 at the
70 mg/m2/day dose level. Fatigue was a relatively common
complaint, but it was not dose related and generally occurred in
association with diarrhea and/or disease progression.
Hematological Toxicity. Hematological toxicities were
generally mild or moderate in severity. Anemia was the most
common hematological effect noted during treatment. Seven-
teen patients (85%) had at least grade 1 anemia, but the anemia
predated the onset of S-1 treatment in eight subjects. One patient
developed abrupt worsening of preexisting anemia from grade 2
to 4 after one course of S-1, and three subjects developed grade
3 anemia during therapy. In one of these subjects, anemia was
attributed to progressive disease involving the gastrointestinal
tract. In another individual, a myelodysplastic syndrome, which
was attributed to previous treatment with a nitrosourea and
mitomycin C, was documented. Three patients required trans-
fusions of red blood cells.
Effects on neutrophils and platelets were uncommon. Four
(20%) and three (15%) patients developed neutropenia and
thrombocytopenia, respectively. All neutropenic events were
mild to moderate in severity and occurred after treatment at the
two highest S-1 dose levels. Thrombocytopenia was always
mild (grade 1), except for a grade 3 event experienced during the
tenth course in a patient who experienced several episodes of
grade 1 thrombocytopenia during earlier courses and was sub-
sequently determined to have a myelodysplastic syndrome, as
discussed previously.
Antineoplastic Activity. Ten (50%) patients experi-
enced either objective antitumor activity or stable disease as
their best response to S-1. Clear evidence of antineoplastic
activity was noted in two patients. The first patient, a 60-year-
old male with colorectal carcinoma and hepatic and pulmonary
metastases that were previously demonstrated to be refractory to
5-FU, irinotecan, and pemetrexed, experienced a 93% reduction
in the size of lesions (partial response) after treatment with two
courses of S-1 at the 60 and 70 mg/m2/day dose levels. He
received five additional courses of S-1 at 50 mg/m2/day but
experienced progressive disease at 10 months. The second pa-
tient, a 67-year-old male with metastatic colorectal carcinoma
that had progressed during prior treatment with 5-FU, irinote-
can, and several investigational agents, experienced a 49%
reduction in the size of lesions. Tumor regression was docu-
mented after two courses of S-1 at the 60 and 50 mg/m2/day
dose levels. He received three additional courses of S-1 at the 50
mg/m2 dose level, but progressive disease was documented at 6
months after the initiation of treatment. Two other patients with
metastatic colorectal carcinoma that had clearly progressed im-
mediately before the onset of therapy with S-1 experienced
stable disease of notable duration. The first patient, a 71-year-
old male whose disease had been demonstrated to be refractory
to regimens consisting of 5-FU/methotrexate/carmustine/mito-
mcyin C and 5-FU/leucovorin, as well as several investigational
agents, experienced substantial improvement in disease-related
pulmonary symptoms and his performance status and stable
disease that persisted during 10 courses of S-1 at the 50 mg/m2/
day dose level. Another individual, a 63-year-old male whose
metastatic colorectal carcinoma had progressed through treat-
ment with 5-FU/leucovorin/irinotecan and several investiga-
tional agents, experienced considerable improvement in disease-
related symptoms and stable disease during six courses of S-1
treatment at the 50 mg/m2/day dose level. Six other patients had
stable disease as their best response.
Pharmacokinetics. Plasma sampling was performed for
pharmacokinetic studies in eight and five patients treated with
S-1 at the 50 and 60 mg/m2/day dose levels, respectively, but
sampling was incomplete in the patients treated at the 70 mg/
m2/day dose level due to the interruption of treatment for
toxicity in course 1. In most subjects, plasma concentrations
were quantifiable until 24 h for tegafur and CDHP and until 8 h
for 5-FU and oxonic acid. Mean plasma concentration versus
time profiles for tegafur, 5-FU, DHDP, and oxonic acid from
plasma sampling performed on the last day of the first course are
shown in Fig. 1, and mean pharmacokinetic parameters for these
S-1 components derived using noncompartmental methods are
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listed in Table 4. For tegafur, dose-related increases in Cmax and
AUC(TAU) were observed between 50 and 60 mg/m2/day. For
5-FU, CDHP, and oxonic acid, Cmax and AUC(TAU) values
appeared to be reasonably similar between the two dose levels.
Gastrointestinal absorption of S-1 was rapid, with Cmax
values for tegafur and CDHP observed at 1.5 and 1.75 h,
respectively, whereas Cmax values for oxonic acid and 5-FU
were noted at 2.5 and 3.0 h, respectively, after treatment with
S-1. Elimination t1/2 values for tegafur were higher than those of
5-FU (mean  SD, 12.1  2.5 versus 3.4  1.7 h). Mean 5-FU
trough concentrations at steady-state measured on days 6, 13,
20, and 27 ranged from 1.06 to 14.56 ng/ml at the 50 and 60
mg/m2/day dose levels, respectively, but several values were
below the level of assay detection. Interestingly, two of three
patients treated in the 70 mg/m2/day cohort had extraordinarily
high 5-FU trough concentrations on day 6 (7.63 and 12.36
ng/ml), which may explain the occurrence of dose-limiting
toxicity in both patients during course 1.
Relationships between pharmacokinetic parameters reflect-
ing exposure to the principal components of S-1 and both
demographic and toxicological elements were sought, but none
were strong. Moderate relationships between the severity of
diarrhea, as assessed by National Cancer Institute Common
Toxicity Criteria grade, and the AUC(TAU) of 5-FU (r 
0.5752; P 0.0504; Fig. 2) and age and the clearance of tegafur
(r0.5620; P 0.0456) were evident. The effects of gender,
liver metastases, and hepatic dysfunction on the exposure of the
principal metabolites of S-1 could not be adequately assessed
because of the small numbers of females, subjects with liver
Table 4 Noncompartmental pharmacokinetic parameters
S-1 dose
(mg/m2/day)
Cmax
(ng/ml)
Tmax
(h)
AUC (TAU)
(ng-h/ml)
Half-life
(h)
Tegafur
50 (n  8) 3353 (1228) 1.5 38763 (17400) 12.4 (3.5)
60 (n  5) 3918 (57) 1.0 48646 (11232) 11.5 (2.2)
5-FU
50 (n  8) 208 (68) 3.0 1541 (426) 3.4 (1.9)
60 (n  5) 189 (55) 3.0 1350 (438) 3.4 (1.4)
CDHP
50 (n  8) 514 (188) 1.75 3600 (1829) 5.8 (2.5)
60 (n  5) 474 (172) 1.5 2938 (684) 4.6 (1.2)
Oxonic acid
50 (n  8) 135 (158) 2.5 976 (1119) 6.1 (4.1)
60 (n  5) 82 (73) 3.0 880 (969) 7.8 (7.0)
NOTE. Values represent mean (SD) values. Median values are
listed for Tmax.
Abbreviations: AUC, area under the concentration-time curve;
Cmax, peak plasma concentration; Tmax, time to peak plasma concen-
tration.
Fig. 1 Mean plasma concen-
tration versus time curves of
S-1 components and 5-FU.
AD, mean plasma concentra-
tion versus time curves of (A)
tegafur, (B) 5-FU, (C) CDHP,
and (D) oxonic acid. Bars, SD.
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metastasis, and those with hepatic dysfunction who had plasma
sampled for pharmacokinetic studies.
DISCUSSION
The inactivation of both dihydropyrimidine dehydrogenase
and orotate phosphoribosyl transferase by the CDHP and oxonic
acid component of S-1 represents a highly effective means of
increasing the therapeutic index of 5-FU, particularly when
administering oral 5-FU or 5-FU prodrugs, which, historically,
have been associated with unpredictable bioavailability, phar-
macokinetics, and erratic toxicity (38–41). Dihydropyrimidine
dehydrogenase is principally responsible for the disposition of
5-FU and its erratic oral bioavailability and large intersubject
variation in pharmacokinetics and toxicity (4, 5, 12–16). The
inactivation of dihydropyrimidine dehydrogenase is attractive
for modulating fluoropyrimidine-based therapy because it may
(a) ensure predictable oral administration of 5-FU because di-
hydropyrimidine dehydrogenase is principally responsible for
the catabolism and erratic bioavailability of oral 5-FU; (b) result
in more predictable pharmacological and toxicological profiles
by decreasing intersubject variability in 5-FU clearance; (c)
improve the toxicity profile of 5-FU by decreasing the formation
of toxic metabolites; (d) enhance antitumor activity by suppress-
ing 5-FU catabolism in tumors; and (e) provide the benefits of
continuous 5-FU administration without requiring central ve-
nous access and cumbersome infusion pumps. Although the
therapeutic merits of inhibiting orotate phosphoribosyl transfer-
ase have been less thoroughly investigated, the principal objec-
tive of this maneuver is to decrease the incidence and severity of
diarrhea due to protracted fluoropyrimidine exposure.
From a pharmaceutical standpoint, the availability of tega-
fur and the dihydropyrimidine dehydrogenase inhibitor CDHP
in a combined oral dosing form reduces the likelihood of ad-
ministering inadvertently high or low doses of tegafur. The most
serious concern is that the inadvertent administration of even a
slightly higher than appropriate dose of 5-FU in a CDHP-
induced dihydropyrimidine dehydrogenase-deficient state may
result in severe toxicity. Additionally, the availability of sepa-
rate oral dosing forms increases the likelihood that patients will
be treated with inappropriately low doses of CDHP, which can
result in low tegafur absorption and therapeutic efficacy. Similar
concerns exist for the development of tegafur/5-FU and inhib-
itors of orotate phosphoribosyl transferase as separate formula-
tions. For these reasons, S-1, a fixed combination of tegafur,
CHDP, and oxonic acid, has been developed. Furthermore, the
use of a combined formulation ensures the administration of all
three components in a fixed ratio, which has resulted in an
optimal therapeutic index in experimental animal tumor models
(19). The principal objective of the present study was to char-
acterize the safety and pharmacokinetics of S-1 administered
once daily for 28 days every 5 weeks and to recommend a dose
for disease-directed studies on this schedule.
The results of the present study demonstrated that the
maximum tolerated dose of S-1 is 50 mg/m2/day when admin-
istered to patients with advanced cancer once daily for 28 days,
followed by a 1-week drug-free period. To recommend a clin-
ically relevant oral dose of S-1 that would be tolerated for
protracted period, the derivation of the maximum tolerated dose
and recommended Phase II dose was based on the incidence of
unacceptable toxicities occurring during the first two 35-day
courses. Unacceptably high incidences of dose-limiting toxici-
ties, principally severe and unmanageable diarrhea or moderate
diarrhea requiring the interruption of S-1 treatment, were ob-
served at S-1 dose levels above 50 mg/m2/day. Furthermore,
diarrhea was also compounded by other, perhaps more worri-
some manifestations of fluoropyrimidine-induced enteritis, par-
ticularly ileus, at high doses. In essence, oxonic acid did not
drastically modify the toxicological profile of protracted fluoro-
pyrimidine administration. However, although it is clear that the
oxonic acid component of S-1 did not completely prevent the
development of diarrhea, the incidence and severity of diarrhea
appeared to be dose related, predictable, and not erratic. At the
60 and 70 mg/m2/day dose levels, four of eight (50%) patients
and two of three (66%) patients experienced dose-limiting tox-
icity during the first two courses of S-1. Interestingly, patients
who tolerated at least two courses of S-1 at the 60 mg/m2/day
dose level without unacceptable toxicity did not experience
dose-limiting events after successive treatment at the same dose
level. At 50 mg/m2, the maximum tolerated dose and recom-
mended dose, none of the nine patients experienced dose-
limiting toxicity during their first two courses and only 1 of 47
(2%) courses was associated with dose-limiting toxicity.
The maximum tolerated dose and recommended Phase II
doses derived in the present study are similar to those deter-
mined in other investigations in North America. For example,
the maximum tolerated dose and recommended Phase II doses
in this study were identical to those reported by Cohen et al.
(42), who evaluated S-1 on a once-daily-for-21-day dosing
schedule, and slightly lower than those reported by Hoff et al.
(27), who recommended 30 mg/m2 twice daily for 28 days every
35 days for subsequent Phase II studies. In a European trial,
slightly higher S-1 doses, 40 and 35 mg/m2 twice daily for 28
days every 35 days, were recommended for Phase II studies in
untreated and previously treated patients, respectively (26). In
all of these investigations, diarrhea was the principal dose-
limiting toxicity. In contrast, myelosuppression was the princi-
pal toxicity that has precluded dose escalation in studies con-
ducted in Japan, whereas gastrointestinal effects were generally
Fig. 2 Scatterplot of AUC(TAU) values for 5-FU as a function of
National Cancer Institute Common Toxicity Criteria grade of diarrhea in
course 1 (r  0.5752; P  0.0504).
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mild and infrequent (28). Furthermore, maximum tolerated
doses were slightly higher in the Japanese study, as calculated
by Hoff et al. (27), than those derived in North American and
European studies (26, 42). The precise explanation for these
differences is not clear at this juncture, however, pharmacoge-
netic differences between Western and Japanese patients have
been proposed (27). Although the pharmacokinetic behavior of
S-1 and its components, particularly parameters that reflect drug
exposure, in the present study are strikingly similar to those
previously reported in North American and European investi-
gations, Hoff et al. (27) have noted that 5-FU AUC values were
similar among the various trials, but tegafur AUC values were
much higher in Japanese patients. This observation, which is
further supported by the present study, has raised the question as
to whether pharmacogenetic variability could account for the
quantitative and qualitative differences in the toxicity profile
between Japanese and Western studies. In support of such
speculation is the demonstration that Japanese individuals ex-
press cytochrome P-450 isoenzyme CYP2A6, which is the prin-
cipal enzyme responsible for the biotransformation of tegafur to
5-FU, to a much greater degree than Caucasians (43).
S-1 was rapidly absorbed from the gastrointestinal tract,
with tegafur and 5-FU plasma concentrations peaking at 1.5 and
3 h posttreatment, respectively. As discussed previously, the
pharmacokinetic behavior of S-1 and its components was sim-
ilar to that reported in previous trials of S-1 on a wide range of
schedules. Furthermore, the pharmacokinetic parameters reflect-
ing systemic exposure of the principal constituents were nearly
identical to those reported in studies evaluating twice-daily
administration of S-1, which has been the principal mode of S-1
administration in Japan and elsewhere (26–28). For tegafur,
dose-related increases in Cmax and AUC values were observed
between the 50 and 60 mg/m2/day dose levels. For 5-FU,
CDHP, and oxonic acid, however, these values appeared to be
reasonably similar. Although this observation may be due to the
small absolute differences between these dose levels, a saturable
biotransformation process from tegafur to 5-FU may also be
raised as an alternate explanation. Most importantly, the clear-
ance of 5-FU resulting from S-1 was remarkably higher than
that reported with 5-FU as an intravenous infusion due to its
potent dihydropyrimidine dehydrogenase inhibitor constituent
CDHP, with t1/2 values averaging 3.4 h compared with 10–20
min (2, 15). From a pharmacological standpoint, this observa-
tion is similar to those reported with other attempts to biomodu-
late 5-FU using dihydropyrimidine dehydrogenase inhibitors in
oral formulations such as eniluracil (eniluracil/5-FU) and uracil
(UFT), in that the pharmacokinetic parameters that reflect 5-FU
exposure, such as AUC and mean trough concentration,
achieved with all formulations administered for 28 days simu-
late those achieved with 5-FU administered as a continuous
intravenous infusion for 28 days (18, 41, 44–46). In the present
study, 5-FU trough concentrations were nearly identical to
steady-state 5-FU concentrations reported with 5-FU adminis-
tered as a continuous infusion at 300 mg/m2/day for 28 days (45,
46). With regard to the relative potency of dihydropyrimidine
dehydrogenase inhibition conferred by uracil and CDHP in UFT
and S-1, respectively, a proposed theoretical dose of 300 mg/m2
of UFT results in a steady-state 5-FU AUC value of 226 ng-h/
ml; however, a 50 mg/m2 dose of S-1 results in a steady-state
5-FU AUC value of 1541 ng-h/ml, which means that a 6-fold
reduction in the tegafur dose (300 to 50 mg/m2; doses based on
tegafur content) results in an approximately 7-fold higher expo-
sure of 5-FU from S-1 compared with UFT (18). This is pre-
sumably due to CDHP being a much more potent inhibitor of
dihydropyrimidine dehydrogenase than uracil.
The results of this study support those of previous Phase I
studies of S-1 administered on other schedules, as well as
disease-directed studies, suggesting that the further development
of the agent is warranted, particularly in the treatment of gas-
trointestinal malignancies. However, it is clear that additional
efforts in terms of schedule optimization may be warranted. For
example, administration schedules with built-in drug-free rest
periods or developing criteria for drug discontinuation after the
development of toxicity may hypothetically permit the sustained
delivery of biologically relevant doses and a higher therapeutic
index. Regardless, the results of Phase II studies of S-1 on dose
schedules similar to that evaluated in the present study in
patients with metastatic gastric and colorectal cancers have been
especially intriguing. In one Phase II study of patients with
metastatic gastric cancer, a 44% response rate was reported, and
only 12% of patients experienced grade 3–4 toxicity after treat-
ment with 40–60 mg/m2 of S-1 twice daily (29). In addition, a
35% response rate with grade 3–4 toxicities, principally neu-
tropenia, in 13% of patients has been noted in patients with
metastatic colorectal cancer treated with S-1 as a single agent
(30). With the availability of a wide variety of oral fluoropyri-
midines, further evaluations to discern their relative merits and
to determine whether the therapeutic index of fluoropyrimidine
therapy may be higher for any particular subpopulation of
patients in treating specific malignancies based on biochemical
determinants may be warranted.
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